NCT06328283 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Mir IH, Guha S, Behera J, Thirunavukkarasu C
Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy. Cell Biol Int. 2021 Nov;45(11):2161-2177. doi: 10.1002/cbin.11670. Epub 2021 Aug 1.
Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS
Biomarkers for hepatocellular cancer. World J Hepatol. 2020 Sep 27;12(9):558-573. doi: 10.4254/wjh.v12.i9.558.
Terentiev AA, Moldogazieva NT
Alpha-fetoprotein: a renaissance. Tumour Biol. 2013 Aug;34(4):2075-91. doi: 10.1007/s13277-013-0904-y. Epub 2013 Jun 14.
Wasfy RE, Shams Eldeen AA
Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions. Asian Pac J Cancer Prev. 2015;16(11):4769-75. doi: 10.7314/apjcp.2015.16.11.4769.

The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of GLutamine Synthetase and BCLAF1 in Diagnosis of Hepatocellular in Cirrhotic Patients

Details for clinical trial NCT06328283

Clinical trial NCT06328283 - References